Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia.
Adult
Aged
Aged, 80 and over
Benzoates
/ therapeutic use
Female
Follow-Up Studies
Humans
Hydrazines
/ therapeutic use
Male
Middle Aged
Prognosis
Purpura, Thrombocytopenic, Idiopathic
/ blood
Pyrazoles
/ therapeutic use
Receptors, Fc
/ therapeutic use
Receptors, Thrombopoietin
/ agonists
Recombinant Fusion Proteins
/ therapeutic use
Retrospective Studies
Survival Rate
Thrombopoietin
/ therapeutic use
Young Adult
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
13 11 2019
13 11 2019
Historique:
received:
29
08
2019
accepted:
25
10
2019
entrez:
15
11
2019
pubmed:
15
11
2019
medline:
13
11
2020
Statut:
epublish
Résumé
Very few data exist on when a particular thrombopoietin-receptor agonist (TPO-RA) is favored in clinical practice for the treatment of patients with immune thrombocytopenia (ITP), about novel risk factors for vascular events (VE) with these drugs, nor about predictive factors for therapy free responses (TFR). We conducted an observational, retrospective, long-term follow-up multicenter study from November 2016 to January 2018 of 121 adult ITP patients initiating TPO-RA between January 2012 to December 2014. Data reflected that a platelet count ≤25 × 10
Identifiants
pubmed: 31723222
doi: 10.1038/s41598-019-53209-y
pii: 10.1038/s41598-019-53209-y
pmc: PMC6853922
doi:
Substances chimiques
Benzoates
0
Hydrazines
0
Pyrazoles
0
Receptors, Fc
0
Receptors, Thrombopoietin
0
Recombinant Fusion Proteins
0
Thrombopoietin
9014-42-0
romiplostim
GN5XU2DXKV
eltrombopag
S56D65XJ9G
Types de publication
Journal Article
Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
16680Commentaires et corrections
Type : ErratumIn
Références
Int J Technol Assess Health Care. 2014 Jan;30(1):129-30
pubmed: 24485057
Front Immunol. 2019 Jun 04;10:1196
pubmed: 31214173
Ther Adv Hematol. 2019 May 09;10:2040620719837906
pubmed: 31156798
Ter Arkh. 2018 Aug 17;90(7):70-76
pubmed: 30701925
J Oncol Pharm Pract. 2019 Apr;25(3):567-576
pubmed: 29298625
Br J Haematol. 2018 Nov;183(3):479-490
pubmed: 30191972
Thromb Haemost. 2017 Jan 5;117(1):57-65
pubmed: 27709226
PLoS One. 2018 Jun 1;13(6):e0198504
pubmed: 29856837
Hematology. 2019 Dec;24(1):290-299
pubmed: 30661482
Eur J Haematol. 2017 Mar;98(3):242-249
pubmed: 27797414
Rev Med Interne. 2017 Mar;38(3):167-175
pubmed: 27793553
Lancet. 2009 Feb 21;373(9664):641-8
pubmed: 19231632
Hematol Transfus Cell Ther. 2018 Jan-Mar;40(1):50-74
pubmed: 30057974
Oncol Res Treat. 2018;41 Suppl 5:1-30
pubmed: 30235458
Am J Hematol. 2018 Jan;93(1):58-64
pubmed: 28983953
Br J Haematol. 2016 Jan;172(2):262-73
pubmed: 26537623
Autoimmun Rev. 2017 Jun;16(6):620-632
pubmed: 28428120
Acta Neurol Scand. 2009 Jan;119(1):1-16
pubmed: 18616624
Transfusion. 2013 Nov;53(11):2807-12
pubmed: 23451917
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Br J Haematol. 2019 May;185(3):503-513
pubmed: 30793285
Br J Haematol. 2007 Jul;138(2):245-8
pubmed: 17542983
Am J Hematol. 2015 Mar;90(3):E40-3
pubmed: 25400215
Thromb Res. 2019 Jun;178:124-131
pubmed: 31026663
Haematologica. 2019 Jun;104(6):1112-1123
pubmed: 31073079
Lancet. 2008 Feb 2;371(9610):395-403
pubmed: 18242413
Blood. 2013 Sep 5;122(10):1712-23
pubmed: 23908465
Blood Transfus. 2018 May;16(3):307-312
pubmed: 28151387
Am J Hematol. 2016 Jan;91(1):39-45
pubmed: 26547507
PLoS One. 2014 Feb 11;9(2):e88283
pubmed: 24523883